Key facts
Home / Investor relations / Key facts
Financial results (Full-year 2023)
Total Revenue
Changes at constant exchange rates
Core Earnings per Share
Changes at constant exchange rates
Full Year and Q4 2023 results
8 February 2024
SEC filings
SEC filings are those documents that we are required to file by virtue of our listing on Nasdaq. They contain mainly financial information.
These documents are also available for viewing on the SEC website at www.sec.gov. The Company will send any holder of the Company’s securities, upon request, a hard copy of the Company’s complete audited financial statements free of charge. Requests may be made by writing to:
Company Secretary
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
Our pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
189
20
3
Contact us
Investor enquiries
Main Contacts
Andy Barnett
Head of Investor Relations
Morgan Sanford
Oncology
Christer Gruvris
BioPharmaceuticals
(Cardiovascular, Renal and Metabolism),
Finance & Fixed Income
Lauren Swales
Rare Disease
Isabel Gibson
Oncology
Philip Sparks
BioPharmaceuticals
(Vaccines & Immune Therapies)
Rachel Korolyshun
Rare Disease,
Environment, Social and Governance
Elizabeth Walton
BioPharmaceuticals
(Respiratory & Immunology), Environment, Social and Governance
-
Annual reports
Our Annual Report provides a wide range of information about our global business.
-
Our Pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development
